Home > Boards > US OTC > Miscellaneous > Enzolytics Inc. (ENZC)

ENZC Big News 11/13/2020 https://finance.yahoo.com/news/enzolytics-inc-shares-current-bioclonetics-

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (4) | Next 10 | Previous | Next
BigJuan Member Profile
Member Level 
Followed By 705
Posts 33,236
Boards Moderated 12
Alias Born 10/26/12
160x600 placeholder
The Emerging Growth Conference is Today April 14 Register now - CEO's Presenting InvestorsHub NewsWire - 4/14/2021 6:30:00 AM
CEO's Presenting on the Emerging Growth Conference on April 14.  Register now. InvestorsHub NewsWire - 4/13/2021 8:18:50 AM
CEO's Presenting on the Emerging Growth Conference on April 14.  Register now. InvestorsHub NewsWire - 4/12/2021 6:47:25 AM
Epazz, Inc. (OTC Pink: EPAZ) Drone Video Release now Live InvestorsHub NewsWire - 3/25/2021 6:00:00 AM
CLS Holdings, (OTCQB: CLSH) $1.49 million Net Revenue for Feb Highest in Company History InvestorsHub NewsWire - 3/9/2021 6:37:33 AM
CLS Holdings, (OTCQB: CLSH) Record January NET Revenue of $1.48 Million Beating Target InvestorsHub NewsWire - 2/9/2021 6:48:48 AM
CLS Holdings, (OTCQB: CLSH) $17 million Sales, 60% Growth & 5 New Products InvestorsHub NewsWire - 2/2/2021 6:52:54 AM
WSGF's, Vaycaychella, Heats Up In $32 Billion Caribbean Vacation Market; Adds Six-Room Hotel To Portfolio Interests InvestorsHub NewsWire - 1/22/2021 9:48:20 AM
Epazz, Inc. (OTC Pink: EPAZ) Enters Blockchain and Cryptocurrency InvestorsHub NewsWire - 1/12/2021 6:00:00 AM
The FDA Calendar Review Dates Can Play a Big Role in Timing Your Trades, But Not the Way You May Think InvestorsHub NewsWire - 1/7/2021 8:00:00 AM
Epazz, Inc. (OTC Pink: EPAZ) Emerging in Blockchain and Cryptocurrency InvestorsHub NewsWire - 1/6/2021 6:00:00 AM
Epazz, Inc. (OTC Pink: EPAZ) Tapping Blockchain & Cryptocurrency with IEO InvestorsHub NewsWire - 12/30/2020 6:00:00 AM
Biotech Companies; Recent Milestones and Potential Upside InvestorsHub NewsWire - 12/22/2020 8:05:00 AM
Penny Stocks on the Move: SFOR and WSGF InvestorsHub NewsWire - 12/10/2020 3:38:16 PM
TNS is on the Hunt for the Next OTC Home Run Stock, Feature Report InvestorsHub NewsWire - 11/30/2020 8:20:00 AM
PURA Launches Hemp Farming Co-Op Campaign InvestorsHub NewsWire - 11/23/2020 1:36:12 PM
ATDS - Cloud Computing Data Security Leader Data443 Eliminates 300M Warrants Removing Overhang For PPS Appreciation And Uplist InvestorsHub NewsWire - 11/18/2020 2:27:56 PM
Epazz, Inc. (OTC Pink: EPAZ) - Expands Internationally Sales will be seen on Q3 Financials InvestorsHub NewsWire - 11/6/2020 6:03:06 AM
ATDS Q3 RPT Likely To Trigger PPS Rebound InvestorsHub NewsWire - 10/30/2020 11:30:04 AM
ATDS Breakout Is Inevitable - Q3 Filing Could Be Trigger InvestorsHub NewsWire - 10/21/2020 1:00:08 PM
Epazz, Inc. (OTC Pink: EPAZ) - Healthcare & Government Contracts and now Education InvestorsHub NewsWire - 9/22/2020 6:25:59 AM
BigJuan Member Level  Friday, 11/13/20 09:40:42 AM
Re: None
Post # of 105719 
ENZC Big News 11/13/2020


PLANO, TX / ACCESSWIRE / November 13, 2020 / Enzolytics Inc. (OTC PINK:ENZC) or the "Company" today shared the following update provided by ENZC's Merger target BioClonetics Immunotherapeutics, Inc. ("BCLS" or "BioClonetics"), resulting from the application of proceeds from the initial funding received on October 26, 2020. The full text of the update is presented below.

November 13, 2020

Dear Investors and Supporters, We are making great progress on our plans to further develop additional anti-HIV monoclonal antibodies and to now begin the production of fully human monoclonal antibodies targeting the CoronaVirus. On December 1, we are expanding our lab to the campus of Texas A&M University at its Institute for Preclinical Studies. This expansion will allow us to complete production of monoclonal antibodies against both the HIV virus and the CoronaVirus and collaborate with the biopharma experts on the campus. Although we have NIH grant applications pending for the production of anti-HIV and anti-CoronaVirus monoclonal antibodies, we have secured funding that allows us to proceed without delay.

We welcome the recent news from Eli Lilly regarding its production of monoclonal antibodies for treatment of COVID-19 patients. We note that experts agree that for a monoclonal antibody therapy to be effective, a "combination" (or "cocktail") of such antibodies used in combination will likely be needed. Dr. Anthony Fauci, head of NIAID/NIH, has repeatedly clarified (as recently in his keynote address at the AIDS International Conference) that a success in treatment of such viruses can be expected to be found in the use of multiple broadly neutralizing HIV antibodies - meaning several antibodies that neutralize a broad spectrum of a virus in its numerous mutation forms.

Thus, we recognize that while other pharma companies may produce effective antibodies, there will necessarily be a need for additional monoclonal antibodies to be used in tantum with those initially discovered. Also, and unfortunately, the mutation of viruses, both the HIV and the CoronaVirus, will necessitate the production of numerous effective antibodies as the virus mutates around the therapeutics initially discovered.

Here is why we are confident in our technology.
It will be imperative that produced antibodies target a conserved and immutable site on the virus - otherwise the antibody (over time) will be rendered ineffective due to mutation - known as "virus escape". Our anti-HIV monoclonal antibody targets an immutable virus site on the HIV virus - one that is constant within virtually all 6000 now known different HIV isolates (strains) of the virus. The CoronaVirus has structure correlative to that of the HIV virus. Because our primary anti-HIV monoclonal antibody has been proven to neutralize numerous different strains of the HIV virus in tests in 5 international labs, and knowing the binding site on the HIV virus to which our antibody binds resulting in neutralization, this knowledge provides insight necessary to identifying corresponding structure (amino acid sequences) on the CoronaVirus that should be targeted to effectively neutralize the CoronaVirus. Moreover, we have proprietary methodology needed to produce anti-CoronaVirus monoclonal antibodies targeting such known - to us - sites.

Thus, while the Eli Lilly monoclonal antibody will hopefully have lasting effect, if it is targeting a mutable site on the virus, the virus may "escape" around it. And indeed, a close look at the results of the Eli Lilly initial tests of its antibody show that the antibody reduced the effect of the virus in some but not all of the patients receiving the antibody.

Thus, even these initial Eli Lilly trials demonstrate that additional monoclonal antibodies can be expected to be needed to fully treat COVID-19 patients.

The procedure for producing monoclonal antibodies is also significant and our procedure differs from those used by other pharma companies. In some cases, other pharma companies produce "humanized" rat and mouse monoclonal antibodies where the original antibody affinity and specificity are not maintained, and the chances of immunogenicity are increased. Our methodology also differs significantly from other pharma approaches using the transgenic mouse model [a human immune system which has been "grafted" within a mouse model] having been "vaccinated" with specific and selected purified CoronaVirus Proteins.

In contrast, our model starts with human "immune-B cells", obtained from convalescent individuals who have recovered from the CoronaVirus. The primary distinction of our process for creating fully human monoclonals is the starting point - namely from human "immune-B cells" from humans who have survived successfully from a "natural" CoronaVirus infection. From these, we then produce antibodies that target conserved immutable sites on the virus - to avoid "virus escape".

Additionally, our antibodies retain the original natural antibody affinity and specificity and have lower risk of immunogenicity when used as a therapeutic. They will provide broad-spectrum coverage against viral variants with increased potency, stability as a single-domain molecule, and, in the recombinant form, will have accessibility to the virus epitopes (binding sites) not accessible with a whole antibody.

We are actively moving forward in our production and testing of such antibodies.

Charles S. Cotropia
BioClonetics Immunotherapeutics, Inc.

The recent appointment of Dr. Ronald Moss to the medical advisory board is another step toward achieving a successful combination of the management and technology teams and business strategies of the two entities. The second tranche of the initial funding is scheduled for receipt early next week and those funds will be used to further our clinical and administrative progress. Final documentation of the combination agreement is currently being reviewed with closing anticipated to be before the end of the month.

If you haven't learned yet, most posts on a message board are in the writer's opinion. All of my posts are in my opinion (IMO)......do your Due Diligence (DD) and make up your own mind!
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (4) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences